重组双特异性抗体的研究进展（待续）

Progress in research of recombinant bispecific antibodies （to be continued）

单克隆抗体由于其靶向性强、副作用小等特点，在肿瘤、免疫系统疾病等多个领域取得了良好的疗效，但是由于只能针对单一明确的靶点，在临床上仍存在一定的局限性。因此，可以同时结合两个相同或者不同抗原上不同表位的双特异性抗体在治疗肿瘤及自身免疫病等领域具有潜在优势。近年来，越来越多不同结构形式的双特异性抗体进入临床试验并取得了良好的疗效。此文对国内外多种适用于大规模生产的重组双特异性抗体结构及其在临床中的应用进行综述。

Monoclonal antibodies have presented great efficacy in a variety of fields such as cancer and immune system disease therapy due to their strong targeting ability and few side effects. However, monoclonal antibodies targeting single specific site have limited clinical application. Therefore, bispecific antibodies binding two different epitopes on the same or different antigens could be potentially applied in tumor and autoimmune disease therapy. In recent years, more and more bispecifie antibodies with different formats have entered clinical trials and achieved high efficacy. In this paper, the structure and clinical applications of various recombinant bispecifie antibodies suitable for large-scale production at home and abroad are reviewed.